BCIRG-001 十年随访:乳腺放疗对心脏病的影响
该研究基于 BCIRG-001 试验对照组 746 例淋巴结阳性早期乳腺癌患者的前瞻性毒性数据,在 10 年随访时比较接受与未接受乳腺放疗者的心脏毒性。结果显示放疗组心律失常更常见,心肌梗死反而更少,心力衰竭无显著差异;但因事件发生率低,需更大样本验证。
要点
- 放疗组心律失常发生率 3.2%,未放疗组 0%(P=.01)。
- 心肌梗死放疗组 0.5% 低于未放疗组 3%(P=.01)。
- 心力衰竭两组无显著差异,需更大样本确认。
核心结论
- 淋巴结阳性早期乳腺癌接受乳腺放疗和统一多柔比星方案化疗后,10 年随访心律失常风险增加,但无明确证据显示心肌梗死或心力衰竭风险显著增加。
研究设计与样本
- 回顾性分析 BCIRG-001 三期试验对照组 746 例接受氟尿嘧啶、多柔比星和环磷酰胺方案化疗的淋巴结阳性早期乳腺癌患者的前瞻性毒性数据,随访 10 年。
- 比较接受放疗与未放疗、左侧放疗与未放疗、内乳淋巴结放疗与未放疗患者的心脏毒性。
主要发现
- 746 例中 559 例(75%)接受放疗,中位剂量 50 Gy。
- 心肌梗死发生于 3 例放疗患者(0.5%)和 6 例未放疗患者(3%)(P=.01)。
- 心力衰竭发生于 15 例放疗患者(2.7%)和 3 例未放疗患者(1.6%)(P=.6)。
- 左心室射血分数较基线相对下降 >20% 见于 35 例放疗患者(18%)和 7 例未放疗患者(10%)(P=.1)。
- 心律失常在放疗患者中更常见(3.2%) versus 未放疗患者(0%)(P=.01)。
关键数值与推荐
- 单变量和多变量分析显示心力衰竭与放疗无显著关联,心肌梗死与放疗呈负相关。
临床怎么用
- 乳腺癌放疗后应关注心律失常风险,心肌梗死和心力衰竭风险在本人群中未显示显著增加。
- 鉴于结局发生率低,需更大样本研究确认上述发现。
局限性
- 为回顾性分析前瞻性毒性数据,结局事件发生率低,需更大样本研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate cardiac toxicity associated with breast radiation therapy (RT) at 10-year follow-up in BCIRG-001, a phase 3 trial comparing adjuvant anthracycline chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide) with anthracycline-taxane chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) in women with lymph node-positive early breast cancer. METHODS AND MATERIALS: Prospective data from all 746 patients in the control arm (fluorouracil, doxorubicin, and cyclophosphamide) of BCIRG-001 at 10-year follow-up were obtained from Project Data Sphere. Cardiac toxicities examined included myocardial infarction (MI), heart failure (HF), arrhythmias, and relative and absolute left ventricular ejection fraction decrease of >20% from baseline. Toxicities were compared between patients who received RT versus no RT, left-sided RT versus no RT, and internal mammary nodal RT versus no RT. RESULTS: Of the 746 patients, 559 (75%) received RT to a median dose of 50 Gy. Myocardial infarction occurred in 3 RT patients (0.5%) versus 6 no-RT patients (3%) (P=.01). Heart failure was seen in 15 RT patients (2.7%) versus 3 no-RT patients (1.6%) (P=.6). Among these, 35 RT patients (18%) had a left ventricular ejection fraction relative decrease of >20% baseline versus 7 (10%) who did not receive RT (P=.1). Arrhythmias were more common in RT patients (3.2%) versus no-RT patients (0%) (P=.01). On univariable and multivariable analysis HF was not significantly associated with RT, and MI was negatively associated with RT. CONCLUSIONS: In this retrospective analysis of prospective toxicity outcomes, there is an increased risk of arrhythmias but no clear evidence of significantly increased risk of MI or HF at 10 years in lymph node-positive women treated with breast RT and uniform adjuvant doxorubicin-based chemotherapy. Given the low incidence of these outcomes, studies with larger numbers are needed to confirm our findings.
引用
- Wu SP, Tam M, Vega RM, et al. Effect of Breast Irradiation on Cardiac Disease in Women Enrolled in BCIRG-001 at 10-Year Follow-Up. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280448. doi:10.1016/j.ijrobp.2017.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。